Coherus Biosciences | CHRS - Debt


Coherus Biosciences reported $294.92M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amarin USD 0 0 Mar/2025
Amgen USD 54.6B 17M Dec/2025
Baxter International USD 9.69B 93M Mar/2026
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Fujifilm JPY 922.82B 236.91B Sep/2025
Gilead Sciences USD 24.94B 5M Dec/2025
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Merck USD 49.34B 7.97B Dec/2025
Myriad Genetics USD 59.3M 19.7M Mar/2025
Pacira USD 367.66M 4.53M Mar/2026
Perrigo USD 3.64B 4.5M Dec/2025
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Teva Pharmaceutical Industries USD 16.91B 187M Mar/2026
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026
Xencor USD 187.75M 118.48M Dec/2025
Zoetis USD 9.24B 1.96B Dec/2025